☆ 4.7 Article

WXJ-202, a novel Ribociclib derivative, exerts antitumor effects against breast cancer through CDK4/6

FRONTIERS IN PHARMACOLOGY (2023)

Related references

Note: Only part of the references are listed.

Review Oncology

The Renaissance of Cyclin Dependent Kinase Inhibitors

Tobias Ettl et al.

Summary: This review provides an overview of CDK inhibitors, focusing on their development and clinical use for the treatment of head and neck cancer. CDK inhibitors have shown potential in combination therapy, enhancing the efficacy of chemo-, radio-, and immunotherapy by overcoming resistance in some tumor types. The success of CDK inhibitors in breast cancer has led to their clinical approval. The review also discusses the molecular mechanisms of CDKs and the latest research on CDK inhibition in the treatment of head and neck cancer.

CANCERS (2022)

Add to Collection

Editorial Material Radiology, Nuclear Medicine & Medical Imaging

18F-FDG PET/CT Metabolic Response With Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Breast Cancer Treated With Cyclin-Dependent 4/6 Kinase Inhibitors

Nuh Filizoglu et al.

Summary: The dysregulation of the cyclin D-CDK4/6-INK4-RB pathway in breast cancer can lead to uncontrolled cell proliferation. Recently, three CDK4/6 inhibitors have been approved by the FDA as first-line treatment for hormone receptor-positive, HER2-negative advanced breast cancer. However, the metabolic response to these new drugs has not been extensively demonstrated.

CLINICAL NUCLEAR MEDICINE (2022)

Add to Collection

Article Cell Biology

Triple-negative and triple-positive breast cancer cells reciprocally control their growth and migration via the S100A4 pathway

Elena A. Dukhanina et al.

Summary: The study aimed to investigate the mechanisms of S100A4 in regulating tumor cell proliferation and migration in breast carcinoma cell lines TPBC and TNBC. TPBC negatively impacted TNBC growth and migration, while extracellular S100A4 reduced TPBC proliferation. The intracellular level of S100A4 in TNBC decreased, with an increase in the dimeric form's contribution to overall S100A4 concentration. The S100A4 pathway involved dexamethasone-sensitive mechanisms in regulating intracellular and extracellular S100A4 pools.

CELL ADHESION & MIGRATION (2022)

Add to Collection

Article Biochemistry & Molecular Biology

Functional characterization of the human Cdk10/Cyclin Q complex

Robert Duester et al.

Summary: In this study, the substrate specificity and function of Cdk10 were thoroughly analyzed, revealing its important role in cell cycle regulation and transcriptional regulation. Cdk10 can act as a tumor suppressor and potentially interact with other CDKs.

OPEN BIOLOGY (2022)

Add to Collection

Article Oncology

ZL-n-91, a specific Phosphodiesterase-4 inhibitor, suppresses the growth of triple-negative breast cancer

Longming Liang et al.

Summary: This study investigated the anticancer effects of a novel PDE4 inhibitor, ZL-n-91, on triple-negative breast cancer (TNBC) and its underlying mechanism. The results showed that ZL-n-91 inhibited TNBC cell proliferation, induced cell apoptosis, and caused cell cycle arrest. It also downregulated cell cycle-related proteins and inhibited the transcription of DNA repair genes, leading to an intracellular DNA damage response. In addition, ZL-n-91 prevented the growth of TNBC tumor xenografts in nude mice. These findings suggest the potential use of ZL-n-91 in anticancer therapy for TNBC.

INVESTIGATIONAL NEW DRUGS (2022)

Add to Collection

Review Medicine, General & Internal

Fertility Counseling in BRCA1/2-Mutated Women with Breast Cancer and Healthy Individuals

Joanna Kufel-Grabowska et al.

Summary: Breast cancer is the most common cancer worldwide, and young women with breast cancer account for a small percentage of cases. The availability of next-generation sequencing has improved the diagnosis and treatment of breast cancer, but the treatment of young breast cancer patients may impact their fertility. Therefore, in addition to oncological treatment, patients need to receive genetic counseling, fertility preservation, and psychological support.

JOURNAL OF CLINICAL MEDICINE (2022)

Add to Collection

Article Oncology

Selective CDK9 Inhibition by Natural Compound Toyocamycin in Cancer Cells

Somnath Pandey et al.

Summary: By combining drug screens, transcriptomic studies, and in vitro assays, our study identified toyocamycin as a potent and selective CDK9 inhibitor. Toyocamycin exhibits specific CDK9 inhibition in cancer cells and has the potential for cancer chemotherapy.

CANCERS (2022)

Add to Collection

Article Oncology

Adjuvant enzalutamide for the treatment of early-stage androgen-receptor positive, triple-negative breast cancer: a feasibility study

Elaine M. Walsh et al.

Summary: This study assessed the feasibility of adjuvant enzalutamide in early-stage, AR-positive TNBC and found that it is a feasible and well-tolerated regimen for this patient population.

BREAST CANCER RESEARCH AND TREATMENT (2022)

Add to Collection

Article Oncology

TRIM35 ubiquitination regulates the expression of PKM2 tetramer and dimer and affects the malignant behaviour of breast cancer by regulating the Warburg effect

Hao Wu et al.

Summary: This study found that TRIM35 regulates the tetramer and dimer transition of PKM2, affecting the Warburg effect and the malignant behavior of breast cancer. Low expression of TRIM35 is associated with shorter overall survival.

INTERNATIONAL JOURNAL OF ONCOLOGY (2022)

Add to Collection

Review Biochemistry & Molecular Biology

Resistance to CDK4/6 inhibition: Mechanisms and strategies to overcome a therapeutic problem in the treatment of hormone receptor-positive metastatic breast cancer

Marios C. Papadimitriou et al.

Summary: Selective CDK4/6 inhibitors are approved for the treatment of HR+, HER2-negative advanced or metastatic breast cancer, but resistance is a major concern. Various mechanisms of resistance have been identified, including cell cycle-related mechanisms and bypass mechanisms. Understanding these mechanisms can aid in the development of new treatment strategies.

BIOCHIMICA ET BIOPHYSICA ACTA-MOLECULAR CELL RESEARCH (2022)

Add to Collection

Article Cell Biology

PSMG2-controlled proteasome-autophagy balance mediates the tolerance for MEK-targeted therapy in triple-negative breast cancer

Xueyan Wang et al.

Summary: By performing a genome-wide CRISPR-Cas9 library screening, researchers discovered that inhibiting PSMG2 can increase the sensitivity of triple-negative breast cancer cells to the MEK inhibitor AZD6244. The mechanism involves impairing proteasome function through PSMG2 knockdown, which activates autophagy-mediated degradation of PDPK1. This degradation enhances the tumor growth inhibition induced by AZD6244 by interrupting negative feedback signals towards the AKT pathway.

CELL REPORTS MEDICINE (2022)

Add to Collection

Review Oncology

Cyclin-dependent kinases in breast cancer: expression pattern and therapeutic implications

Shazia Sofi et al.

Summary: Breast cancer is one of the most common malignancies worldwide, and dysregulation of the cell cycle is an important factor in its development. Cyclin-dependent kinases (CDKs) play a crucial role in the progression and treatment of breast cancer.

MEDICAL ONCOLOGY (2022)

Add to Collection

Review Pharmacology & Pharmacy

Inhibiting CDK4/6 in Breast Cancer with Palbociclib, Ribociclib, and Abemaciclib: Similarities and Differences

C. Louwrens Braal et al.

Summary: CDK 4/6 inhibitors are a new class of drugs that interrupt proliferation of malignant cells by inhibiting progression through the cell cycle. This article reviews the clinical pharmacokinetic and pharmacodynamic profiles of these inhibitors and discusses important future directions for their clinical applicability.

DRUGS (2021)

Add to Collection

Article Oncology

Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries

Hyuna Sung et al.

Summary: The global cancer burden in 2020 saw an estimated 19.3 million new cancer cases and almost 10.0 million cancer deaths. Female breast cancer surpassed lung cancer as the most commonly diagnosed cancer, while lung cancer remained the leading cause of cancer death. These trends are expected to rise in 2040, with transitioning countries experiencing a larger increase compared to transitioned countries due to demographic changes and risk factors associated with globalization and a growing economy. Efforts to improve cancer prevention measures and provision of cancer care in transitioning countries will be crucial for global cancer control.

CA-A CANCER JOURNAL FOR CLINICIANS (2021)

Add to Collection

Review Oncology

Breast cancer brain metastasis: insight into molecular mechanisms and therapeutic strategies

Yajie Wang et al.

Summary: Breast cancer brain metastasis is a common cause of death among breast cancer patients, with poor prognosis due to limited permeability of the blood-brain barrier and lack of effective treatments. While the sequence of metastasis events is accepted, the underlying mechanisms remain to be fully elucidated.

BRITISH JOURNAL OF CANCER (2021)

Add to Collection

Article Oncology

SSi6 promotes cell death by apoptosis through cell cycle arrest and inhibits migration and invasion of MDA-MB-231 human breast cancer cells

Liany Luna-Dulcey et al.

ANTI-CANCER DRUGS (2020)

Add to Collection

Review Environmental Sciences

Triple-Negative Breast Cancer: A Review of Conventional and Advanced Therapeutic Strategies

Mauricio A. Medina et al.

INTERNATIONAL JOURNAL OF ENVIRONMENTAL RESEARCH AND PUBLIC HEALTH (2020)

Add to Collection

Review Biochemistry & Molecular Biology

Senescence as a therapeutically relevant response to CDK4/6 inhibitors

Verena Wagner et al.

ONCOGENE (2020)

Add to Collection

Article Pharmacology & Pharmacy

Bisphenol S promotes the cell cycle progression and cell proliferation through ERα-cyclin D-CDK4/6-pRb pathway in MCF-7 breast cancer cells

Zhenxian Lin et al.

TOXICOLOGY AND APPLIED PHARMACOLOGY (2019)

Add to Collection

Review Oncology

CDK 4/6 Inhibitors in Breast Cancer: Current Controversies and Future Directions

Laura M. Spring et al.

CURRENT ONCOLOGY REPORTS (2019)

Add to Collection

Review Oncology

Molecular mechanisms of resistance to CDK4/6 inhibitors in breast cancer: A review

Kamal Pandey et al.

INTERNATIONAL JOURNAL OF CANCER (2019)

Add to Collection

Review Pharmacology & Pharmacy

Cyclin-dependent protein serine/threonine kinase inhibitors as anticancer drugs

Robert Roskoski

PHARMACOLOGICAL RESEARCH (2019)

Add to Collection

Article Biochemistry & Molecular Biology

Single-cell RNA-Seq reveals cell heterogeneity and hierarchy within mouse mammary epithelia

Heng Sun et al.

JOURNAL OF BIOLOGICAL CHEMISTRY (2018)

Add to Collection

Article Oncology

Cell-Cycle Therapeutics Come of Age

Matthew Ingham et al.

JOURNAL OF CLINICAL ONCOLOGY (2017)

Add to Collection

Article Biochemistry & Molecular Biology

A Cdk7-Cdk4 T-Loop Phosphorylation Cascade Promotes G1 Progression

Miriam Merzel Schachter et al.

MOLECULAR CELL (2013)

Add to Collection

Article Multidisciplinary Sciences

E2F1-Mediated Upregulation of p19INK4d Determines Its Periodic Expression during Cell Cycle and Regulates Cellular Proliferation

Abel L. Carcagno et al.

PLOS ONE (2011)

Add to Collection

Review Oncology

Cyclin D1 in breast cancer pathogenesis

A Arnold et al.

JOURNAL OF CLINICAL ONCOLOGY (2005)

Add to Collection

© Peeref 2019-2024. All rights reserved.